ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)
Phase 3
Completed
- Conditions
- Refractory Generalized Myasthenia Gravis
- Interventions
- Biological: EculizumabDrug: Placebo
- First Posted Date
- 2013-11-28
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT01997229
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸University of California San Francisco-Fresno, Fresno, California, United States
🇺🇸University of California-Irvine, Orange, California, United States
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
Phase 1
Completed
- Conditions
- Follicular Lymphoma (FL/Indolent NHL)Aggressive NHL (a NHL)B-cell Non Hodgkin Lymphoma (NHL)Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)T-cell Lymphoma (PTCL and CTCL)
- Interventions
- Biological: Rituximab
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT01994382
A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
Phase 3
Terminated
- Conditions
- Neuromyelitis Optica Spectrum DisorderNeuromyelitis Optica
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-07-04
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT01892345
- Locations
- 🇺🇸
John Hopkins University School of Medicine, Baltimore, Maryland, United States
🇦🇺University of Sydney, Brain and Mind Center, Camperdown, New South Wales, Australia
🇦🇺St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects
- First Posted Date
- 2013-06-21
- Last Posted Date
- 2014-03-31
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT01883544
- Locations
- 🇺🇸
PAREXEL Baltimore EPCU, Baltimore, Maryland, United States
Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants
Phase 2
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01849562
A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Completed
- Conditions
- Atypical Hemolytic Uremic Syndrome (aHUS)
- First Posted Date
- 2013-01-18
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01770951
The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
- First Posted Date
- 2012-12-31
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT01757431
- Locations
- 🇯🇵
Nagano Red Cross Hospital, Nagano, Japan
🇯🇵Tokyo Medical and Dental University Hospital, Tokyo, Japan
Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency
Phase 3
Completed
- Conditions
- Lysosomal Acid Lipase Deficiency
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-12-28
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT01757184
To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients
Completed
- Conditions
- ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
- First Posted Date
- 2012-12-24
- Last Posted Date
- 2012-12-24
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT01755429
- Locations
- 🇯🇵
Tokyo Medical and Dental University, Tokyo, Japan
🇯🇵Shinshu University School of Medicine, Matsumoto, Japan
Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants
Phase 1
Completed
- Conditions
- Chronic Hepatitis C Infection
- Interventions
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT01700179
© Copyright 2025. All Rights Reserved by MedPath